Axxcess Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Axxcess Wealth Management LLC acquired 439 shares of Regeneron Pharmaceuticals, valued at approximately $230,000, during the second quarter.
• Analysts have raised their price targets for Regeneron, with Guggenheim setting a target at $815.00 and Jefferies Financial Group at $831.00, maintaining a “buy” rating.
• Regeneron Pharmaceuticals reported $12.89 EPS for the latest quarter, exceeding expectations and showing a 3.6% increase in year-over-year revenue.

Axxcess Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 439 shares of the biopharmaceutical company's stock, valued at approximately $230,000.

A number of other hedge funds have also made changes to their positions in REGN. Brighton Jones LLC raised its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the period. GAMMA Investing LLC raised its stake in shares of Regeneron Pharmaceuticals by 41.8% in the 1st quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company's stock valued at $816,000 after acquiring an additional 379 shares during the period. Ritholtz Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 7.8% in the 1st quarter. Ritholtz Wealth Management now owns 486 shares of the biopharmaceutical company's stock valued at $308,000 after acquiring an additional 35 shares during the period. Sowell Financial Services LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $353,000. Finally, Kingswood Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Jefferies Financial Group lifted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 14th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Finally, Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $578.05 on Friday. The firm has a market cap of $61.27 billion, a P/E ratio of 14.57, a P/E/G ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,002.69. The firm has a fifty day moving average of $574.64 and a two-hundred day moving average of $562.46.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the business posted $11.56 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.